Shares of Agenus Inc. (NASDAQ:AGEN) have been given an average rating of “Buy” by the seven research firms that are currently covering the stock. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $12.20.
Several equities analysts have recently commented on the stock. Zacks Investment Research cut shares of Agenus from a “buy” rating to a “hold” rating in a report on Wednesday, September 28th. Maxim Group restated a “buy” rating on shares of Agenus in a report on Wednesday, June 22nd. Jefferies Group boosted their price target on shares of Agenus from $6.00 to $7.00 and gave the company a “buy” rating in a report on Friday, July 29th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Agenus in a report on Sunday, July 31st.
In other Agenus news, Director Ulf Wiinberg acquired 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 6th. The stock was purchased at an average cost of $6.29 per share, for a total transaction of $188,700.00. Following the completion of the acquisition, the director now owns 30,000 shares of the company’s stock, valued at approximately $188,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 7.60% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the company. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Agenus by 4.6% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,860,873 shares of the company’s stock worth $7,537,000 after buying an additional 82,244 shares in the last quarter. BlackRock Investment Management LLC boosted its stake in Agenus by 3.4% in the second quarter. BlackRock Investment Management LLC now owns 288,041 shares of the company’s stock worth $1,167,000 after buying an additional 9,496 shares during the period. BlackRock Advisors LLC boosted its stake in Agenus by 2.2% in the second quarter. BlackRock Advisors LLC now owns 34,250 shares of the company’s stock worth $139,000 after buying an additional 722 shares during the period. Vanguard Group Inc. boosted its stake in Agenus by 6.3% in the second quarter. Vanguard Group Inc. now owns 2,976,529 shares of the company’s stock worth $12,055,000 after buying an additional 176,136 shares during the period. Finally, Blair William & Co. IL boosted its stake in Agenus by 45.9% in the second quarter. Blair William & Co. IL now owns 59,700 shares of the company’s stock worth $189,000 after buying an additional 18,775 shares during the period. Hedge funds and other institutional investors own 40.64% of the company’s stock.
Shares of Agenus (NASDAQ:AGEN) opened at 5.86 on Thursday. Agenus has a 12 month low of $2.61 and a 12 month high of $7.49. The stock’s 50 day moving average price is $6.69 and its 200-day moving average price is $5.06. The stock’s market capitalization is $509.30 million.
Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, July 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01. Agenus had a negative net margin of 328.53% and a negative return on equity of 138.27%. The company had revenue of $6.59 million for the quarter, compared to the consensus estimate of $5.12 million. Equities analysts forecast that Agenus will post ($1.27) earnings per share for the current fiscal year.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.